Do analysts recommend ABVC or CVKD?

Cadrenal Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 915.63%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than ABVC BioPharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ABVC BioPharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ABVC or CVKD more profitable?

ABVC BioPharma's return on equity of -47.68% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets ABVC BioPharma N/A -47.68% -30.97% Cadrenal Therapeutics N/A -406.41% -273.80%

Does the media refer more to ABVC or CVKD?

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than ABVC BioPharma. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 1 mentions for ABVC BioPharma. Cadrenal Therapeutics' average media sentiment score of 0.76 beat ABVC BioPharma's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ABVC BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cadrenal Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer CVKD or PLRZ?

Cadrenal Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 915.63%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Polyrizon. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Polyrizon 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings and valuation, CVKD or PLRZ?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Polyrizon N/A N/A -$3.34M N/A N/A

Is CVKD or PLRZ more profitable?

Polyrizon's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Polyrizon N/A N/A N/A

Does the media prefer CVKD or PLRZ?

In the previous week, Cadrenal Therapeutics had 3 more articles in the media than Polyrizon. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 6 mentions for Polyrizon. Cadrenal Therapeutics' average media sentiment score of 0.76 beat Polyrizon's score of 0.54 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Polyrizon 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts prefer BFRI or CVKD?

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 915.63%. Given Cadrenal Therapeutics' higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Biofrontera. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biofrontera 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Do analysts rate CVKD or COCP?

Cadrenal Therapeutics presently has a consensus target price of $13.00, indicating a potential upside of 915.63%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cadrenal Therapeutics is more favorable than Cocrystal Pharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cadrenal Therapeutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Cocrystal Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, CVKD or COCP?

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Cocrystal Pharma N/A N/A -$8.83M -$0.76 N/A

Is CVKD or COCP more profitable?

Cocrystal Pharma's return on equity of -207.47% beat Cadrenal Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Cadrenal Therapeutics N/A -406.41% -273.80% Cocrystal Pharma N/A -207.47% -123.33%

Which has preferable earnings and valuation, CVKD or PSTV?

Plus Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cadrenal Therapeutics N/A N/A -$13.24M -$4.90 N/A Plus Therapeutics N/A N/A -$22.39M -$2.30 N/A

Does the media refer more to CVKD or PSTV?

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than Plus Therapeutics. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 1 mentions for Plus Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.76 beat Plus Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cadrenal Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Plus Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Cadrenal Therapeutics (CVKD) Competitors

$1.28 -0.05 (-3.76%)

As of 09/3/2026 04:00 PM Eastern

Compare

CVKD vs. ABVC, PLRZ, BFRI, COCP, and PSTV

Should you buy Cadrenal Therapeutics stock or one of its competitors? Cadrenal Therapeutics's main competitors and comparable companies include ABVC BioPharma (ABVC), Polyrizon (PLRZ), Biofrontera (BFRI), Cocrystal Pharma (COCP), and Plus Therapeutics (PSTV). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Cadrenal Therapeutics compare to ABVC BioPharma?

ABVC BioPharma (NASDAQ:ABVC) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Cadrenal Therapeutics has a consensus price target of $13.00, suggesting a potential upside of 915.63%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cadrenal Therapeutics is more favorable than ABVC BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ABVC BioPharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

ABVC BioPharma has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than ABVC BioPharma. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 1 mentions for ABVC BioPharma. Cadrenal Therapeutics' average media sentiment score of 0.76 beat ABVC BioPharma's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ABVC BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cadrenal Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

11.4% of ABVC BioPharma shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 19.0% of ABVC BioPharma shares are held by company insiders. Comparatively, 14.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ABVC BioPharma's return on equity of -47.68% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ABVC BioPharma	N/A	-47.68%	-30.97%
Cadrenal Therapeutics	N/A	-406.41%	-273.80%

ABVC BioPharma has higher revenue and earnings than Cadrenal Therapeutics. ABVC BioPharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ABVC BioPharma	$510K	52.25	-$7.91M	-$0.30	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A

Summary

ABVC BioPharma and Cadrenal Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Polyrizon?

Cadrenal Therapeutics (NASDAQ:CVKD) and Polyrizon (NASDAQ:PLRZ) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

Polyrizon's return on equity of 0.00% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Polyrizon	N/A	N/A	N/A

7.9% of Cadrenal Therapeutics shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Cadrenal Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Polyrizon has a beta of -1.39, suggesting that its share price is 239% less volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 3 more articles in the media than Polyrizon. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 6 mentions for Polyrizon. Cadrenal Therapeutics' average media sentiment score of 0.76 beat Polyrizon's score of 0.54 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Polyrizon	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cadrenal Therapeutics presently has a consensus price target of $13.00, suggesting a potential upside of 915.63%. Given Cadrenal Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Cadrenal Therapeutics is more favorable than Polyrizon.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Polyrizon	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Polyrizon	N/A	N/A	-$3.34M	N/A	N/A

Summary

Cadrenal Therapeutics beats Polyrizon on 8 of the 11 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Biofrontera?

Biofrontera (NASDAQ:BFRI) and Cadrenal Therapeutics (NASDAQ:CVKD) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

Cadrenal Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 915.63%. Given Cadrenal Therapeutics' higher probable upside, analysts plainly believe Cadrenal Therapeutics is more favorable than Biofrontera.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Biofrontera has higher revenue and earnings than Cadrenal Therapeutics. Biofrontera is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biofrontera	$41.71M	0.54	-$10.54M	-$0.45	N/A
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A

10.1% of Biofrontera shares are held by institutional investors. Comparatively, 7.9% of Cadrenal Therapeutics shares are held by institutional investors. 8.1% of Biofrontera shares are held by company insiders. Comparatively, 14.6% of Cadrenal Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cadrenal Therapeutics has a net margin of 0.00% compared to Biofrontera's net margin of -13.78%. Biofrontera's return on equity of -145.81% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Cadrenal Therapeutics	N/A	-406.41%	-273.80%

Biofrontera has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market. Comparatively, Cadrenal Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market.

In the previous week, Cadrenal Therapeutics had 9 more articles in the media than Biofrontera. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 0 mentions for Biofrontera. Cadrenal Therapeutics' average media sentiment score of 0.76 beat Biofrontera's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Biofrontera	Neutral
Cadrenal Therapeutics	Positive

Summary

Cadrenal Therapeutics beats Biofrontera on 7 of the 13 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Cocrystal Pharma?

Cadrenal Therapeutics (NASDAQ:CVKD) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Cadrenal Therapeutics presently has a consensus target price of $13.00, indicating a potential upside of 915.63%. Given Cadrenal Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Cadrenal Therapeutics is more favorable than Cocrystal Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Cocrystal Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Cadrenal Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market. Comparatively, Cocrystal Pharma has a beta of 1.48, indicating that its share price is 48% more volatile than the broader market.

Cocrystal Pharma is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Cocrystal Pharma	N/A	N/A	-$8.83M	-$0.76	N/A

Cocrystal Pharma's return on equity of -207.47% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Cocrystal Pharma	N/A	-207.47%	-123.33%

In the previous week, Cadrenal Therapeutics had 9 more articles in the media than Cocrystal Pharma. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 0 mentions for Cocrystal Pharma. Cadrenal Therapeutics' average media sentiment score of 0.76 beat Cocrystal Pharma's score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Cadrenal Therapeutics	Positive
Cocrystal Pharma	Neutral

7.9% of Cadrenal Therapeutics shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 14.6% of Cadrenal Therapeutics shares are owned by company insiders. Comparatively, 39.4% of Cocrystal Pharma shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Cadrenal Therapeutics beats Cocrystal Pharma on 8 of the 13 factors compared between the two stocks.

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Cadrenal Therapeutics (NASDAQ:CVKD) and Plus Therapeutics (NASDAQ:PSTV) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Cadrenal Therapeutics had 8 more articles in the media than Plus Therapeutics. MarketBeat recorded 9 mentions for Cadrenal Therapeutics and 1 mentions for Plus Therapeutics. Cadrenal Therapeutics' average media sentiment score of 0.76 beat Plus Therapeutics' score of 0.00 indicating that Cadrenal Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cadrenal Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Plus Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

7.9% of Cadrenal Therapeutics shares are held by institutional investors. Comparatively, 3.3% of Plus Therapeutics shares are held by institutional investors. 14.6% of Cadrenal Therapeutics shares are held by insiders. Comparatively, 2.5% of Plus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Cadrenal Therapeutics has a net margin of 0.00% compared to Plus Therapeutics' net margin of -230.24%. Plus Therapeutics' return on equity of -198.48% beat Cadrenal Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cadrenal Therapeutics	N/A	-406.41%	-273.80%
Plus Therapeutics	-230.24%	-198.48%	-73.13%

Plus Therapeutics is trading at a lower price-to-earnings ratio than Cadrenal Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cadrenal Therapeutics	N/A	N/A	-$13.24M	-$4.90	N/A
Plus Therapeutics	N/A	N/A	-$22.39M	-$2.30	N/A

Cadrenal Therapeutics presently has a consensus target price of $13.00, suggesting a potential upside of 915.63%. Plus Therapeutics has a consensus target price of $51.75, suggesting a potential upside of 1,660.20%. Given Plus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Plus Therapeutics is more favorable than Cadrenal Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cadrenal Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Plus Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cadrenal Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market. Comparatively, Plus Therapeutics has a beta of 1.4, meaning that its stock price is 40% more volatile than the broader market.

Summary

Cadrenal Therapeutics beats Plus Therapeutics on 8 of the 14 factors compared between the two stocks.

Get Cadrenal Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CVKD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CVKD vs. The Competition

Export

Metric	Cadrenal Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$4.74M	$12.25B	$7.26B	$12.73B
Dividend Yield	N/A	2.59%	2.53%	8.86%
P/E Ratio	-0.26	787.27	273.29	25.38
Price / Sales	N/A	753.78	613.45	97.56
Price / Cash	N/A	94.80	77.82	52.26
Price / Book	1.11	12.33	12.89	6.14
Net Income	-$13.24M	$2.82B	$3.47B	$349.01M
7 Day Performance	-16.88%	2.59%	0.60%	-0.27%
1 Month Performance	-36.95%	6.95%	5.73%	0.68%
1 Year Performance	-89.77%	9.45%	25.35%	14.84%

Cadrenal Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CVKD Cadrenal Therapeutics	2.3638 of 5 stars	$1.28 -3.8%	$13.00 +915.6%	-90.1%	$4.74M	N/A	N/A	4	Analyst Revision Gap Down
ABVC ABVC BioPharma	0.3591 of 5 stars	$0.80 -4.8%	N/A	-63.1%	$22.39M	$510K	N/A	30	News Coverage Gap Up
PLRZ Polyrizon	0.7336 of 5 stars	$10.90 +1.9%	N/A	+99.4%	$22.30M	N/A	N/A	N/A	News Coverage Analyst Downgrade Short Interest Increase Gap Down
BFRI Biofrontera	0.9869 of 5 stars	$1.51 +3.4%	N/A	+73.6%	$21.68M	$41.71M	N/A	70
COCP Cocrystal Pharma	1.186 of 5 stars	$1.13 +1.8%	N/A	-23.4%	$21.38M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CVKD) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. ABVC, PLRZ, BFRI, COCP, and PSTV

How does Cadrenal Therapeutics compare to ABVC BioPharma?

Summary

How does Cadrenal Therapeutics compare to Polyrizon?

Summary

How does Cadrenal Therapeutics compare to Biofrontera?

Summary

How does Cadrenal Therapeutics compare to Cocrystal Pharma?

Summary

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cadrenal Therapeutics (CVKD) Competitors

CVKD vs. ABVC, PLRZ, BFRI, COCP, and PSTV

How does Cadrenal Therapeutics compare to ABVC BioPharma?

Do analysts recommend ABVC or CVKD?

Which has more risk and volatility, ABVC or CVKD?

Does the media refer more to ABVC or CVKD?

Do institutionals and insiders believe in ABVC or CVKD?

Is ABVC or CVKD more profitable?

Which has preferable earnings and valuation, ABVC or CVKD?

Summary

How does Cadrenal Therapeutics compare to Polyrizon?

Is CVKD or PLRZ more profitable?

Do insiders and institutionals hold more shares of CVKD or PLRZ?

Which has more risk and volatility, CVKD or PLRZ?

Does the media prefer CVKD or PLRZ?

Do analysts prefer CVKD or PLRZ?

Which has better earnings and valuation, CVKD or PLRZ?

Summary

How does Cadrenal Therapeutics compare to Biofrontera?

Do analysts prefer BFRI or CVKD?

Which has higher earnings & valuation, BFRI or CVKD?

Do institutionals & insiders hold more shares of BFRI or CVKD?

Is BFRI or CVKD more profitable?

Which has more volatility and risk, BFRI or CVKD?

Does the media favor BFRI or CVKD?

Summary

How does Cadrenal Therapeutics compare to Cocrystal Pharma?

Do analysts rate CVKD or COCP?

Which has more volatility & risk, CVKD or COCP?

Which has better valuation and earnings, CVKD or COCP?

Is CVKD or COCP more profitable?

Does the media prefer CVKD or COCP?

Do insiders and institutionals have more ownership in CVKD or COCP?

Summary

How does Cadrenal Therapeutics compare to Plus Therapeutics?

Does the media refer more to CVKD or PSTV?

Do insiders & institutionals hold more shares of CVKD or PSTV?

Is CVKD or PSTV more profitable?

Which has preferable earnings and valuation, CVKD or PSTV?

Do analysts recommend CVKD or PSTV?

Which has more volatility & risk, CVKD or PSTV?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CVKD vs. The Competition

Cadrenal Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools